Dissemin is shutting down on January 1st, 2025

Published in

Russian Journal of Cardiology, 4S(26), p. 4791, 2021

DOI: 10.15829/1560-4071-2021-4791

Links

Tools

Export citation

Search in Google Scholar

Approaches to the therapy of heart failure with reduced ejection fraction. Resolution of an online meeting of the Volga Federal District experts

Journal article published in 2021 by A. S. Galyavich ORCID, I. V. Fomin ORCID, I. R. Gaisin ORCID, F. V. Valeeva ORCID, N. G. Vinogradova ORCID, A. S. Salasyuk ORCID, E. I. Tarlovskaya ORCID, N. R. Khasanov ORCID, A. M. Shutov ORCID, E. N. Volodina ORCID, L. V. Grekhova, P. S. Guseva, D. V. Duplyakov ORCID, O. V. Zanozina ORCID, Y.-U. V. Zolotova and other authors.
This paper is made freely available by the publisher.
This paper is made freely available by the publisher.

Full text: Download

Question mark in circle
Preprint: policy unknown
Upload
Question mark in circle
Postprint: policy unknown
Upload
Question mark in circle
Published version: policy unknown
Upload

Abstract

At an online meeting of experts held on May 14, 2021 additional research results on a sodium-glucose co-transporter-2 (SGLT2) inhibitor empagliflozin in patients with heart failure with reduced ejection fraction were considered. According to the data from the EMPEROR-Reduced international study, cardiovascular and renal effects of empagliflozin therapy in patients with and without type 2 diabetes (T2D) were analyzed. A number of proposals and recommendations was accepted regarding the further study of cardiovascular and renal effects of empagliflozin and its use in clinical practice in patients with heart failure, regardless of the T2D presence.